← Back to Clinical Trials
Recruiting NCT06169605

NCT06169605 Assessment of the Effect of Tumor Thickness and Site on Level IV Cervical Lymph Nodes in Squamous Cell Carcinoma of the Tongue and Floor of the Mouth: A Case Series Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06169605
Status Recruiting
Phase
Sponsor Cairo University
Condition Tongue Neoplasms
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2024-04-01
Primary Completion 2025-05-30

Eligibility & Interventions

Sex All sexes
Min Age 15 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
removal of primary tumor, neck dissection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2024-04-01 with a primary completion date of 2025-05-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Regarding oral cavity cancer, the high incidence of neck metastasis along with its impact on survival and prognosis are in favor of elective neck dissection. Moreover, occult metastases could develop at lower levels in the neck (levels IV-V) Regarding the tongue, the rate of skip (occult) metastasis involving unremoved level IV cervical lymph nodes in squamous cell carcinoma of the tongue ranges from 0 % - 11.4 %. However, no data is available or a correlation between the risk of level IV involvement and the affection of specific tongue subsites or a certain cutoff value of tumor thickness.

Eligibility Criteria

Inclusion Criteria: * Patients with squamous cell carcinoma of the tongue and floor of the mouth. * Age group: from 15 to 60 years old * No sex predilection Exclusion Criteria: * Patients with recurrent squamous cell carcinoma of the tongue and floor of the mouth. * Irradiated patients or those taking chemotherapy.

Contact & Investigator

Central Contact

Mohamed Shawky, MSc

✉ m.shawky1993@gmail.com

📞 +201223933897

Principal Investigator

Mohamed Shawky, MSc

PRINCIPAL INVESTIGATOR

Cairo University

Frequently Asked Questions

Who can join the NCT06169605 clinical trial?

This trial is open to participants of all sexes, aged 15 Years or older, up to 60 Years, studying Tongue Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06169605 currently recruiting?

Yes, NCT06169605 is actively recruiting participants. Contact the research team at m.shawky1993@gmail.com for enrollment information.

Where is the NCT06169605 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT06169605 clinical trial?

NCT06169605 is sponsored by Cairo University. The principal investigator is Mohamed Shawky, MSc at Cairo University. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology